Pharma Billion-Dollar Deals, AI Collaborations, and Strategic Acquisitions Reshape Industry Landscape

From Otsuka’s $1.2 billion acquisition of Transcend Therapeutics to Novartis’ $12 billion buyout of Avidity Biosciences, the global pharmaceutical industry is witnessing a surge in high-value deals, AI-driven collaborations, and manufacturing alliances. These developments highlight a strong shift toward precision medicine, digital transformation, and next-generation therapeutics.

The global pharmaceutical and life sciences sector is undergoing a transformative phase marked by a series of high-value acquisitions, strategic collaborations, and technology-driven partnerships. Companies across the value chain—from big pharma to AI-native biotech firms—are aggressively expanding capabilities to accelerate innovation, strengthen pipelines, and improve patient outcomes.

One of the most prominent deals comes Otsuka Pharmaceutical, which has entered into an agreement to fully acquire Transcend Therapeutics through its subsidiary Otsuka America. The transaction, expected to close in the second quarter of 2026, includes an upfront payment of USD 700 million and up to USD 525 million in milestone-based payments, bringing the total potential value to USD 1.225 billion. The acquisition is expected to strengthen Otsuka’s presence in neuroscience and mental health therapeutics.

Artificial intelligence continues to play a central role in drug discovery innovation. Insilico Medicine has expanded its collaboration with Tenacia Biotechnology to further develop CNS-targeted therapies with strong blood–brain barrier penetration. Additionally, Insilico has partnered with Liquid AI to develop lightweight AI models for pharmaceutical research. These models allow on-premise deployment, addressing growing concerns around data security while maintaining high performance across drug discovery workflows.

In the digital health and services segment, Infosys has announced the acquisition of Optimum Healthcare IT. The deal enhances Infosys’ capabilities in healthcare digital transformation, enabling provider organizations to leverage advanced AI, cloud, and cybersecurity solutions. This move underscores the increasing convergence of healthcare delivery and digital infrastructure.

Meanwhile, Abbott has completed its acquisition of Exact Sciences, marking a significant step in expanding its leadership in cancer diagnostics. With Exact Sciences now a wholly owned subsidiary, Abbott aims to enhance early cancer detection and personalized treatment solutions for millions of patients worldwide.

AI-driven  Earendil Labs has secured $787 million in financing from a consortium of global investors, including Sanofi and funds backed by Pfizer. The funding will accelerate its biologics pipeline and scale its AI-powered R&D platform, reinforcing the growing investor confidence in AI-first drug development models.

On the manufacturing front, Celltrion has signed a contract manufacturing agreement worth up to KRW 375.4 billion with a global pharmaceutical partner. The deal spans 2027 to 2029 and highlights rising demand for CDMO services. Through Celltrion BioSolutions, the company is strengthening its operational and technological capabilities to deliver high-value manufacturing solutions.

In the cell and gene therapy space, Terumo Blood and Cell Technologies has partnered with Taiwan Bio Therapeutics to automate regulatory T-cell (Treg) manufacturing. The collaboration aims to scale production for therapies such as TRK-001, currently in Phase 2 trials for kidney transplantation, addressing critical challenges in manufacturing consistency and scalability.

Diagnostics and pathology also remain key areas of consolidation. Agilent Technologies has announced a $950 million acquisition of Biocare Medical. The deal enhances Agilent’s cancer diagnostics portfolio and supports its strategy of delivering integrated solutions across clinical and research settings.

In the medical manufacturing sector, Technimark has acquired Rage Custom Plastics, expanding its footprint in healthcare components and strengthening its blow molding capabilities. This acquisition supports growing demand for high-quality medical device manufacturing.

Japanese conglomerate Fujifilm has invested in VALANX Biotech to advance antibody-drug conjugate (ADC) technologies. ADCs are emerging as a critical modality in oncology, offering targeted treatment with reduced side effects, and the partnership aims to strengthen Fujifilm’s CDMO capabilities in this segment.

In regenerative medicine, Catalent has partnered with GelMEDIX to develop iPSC-derived therapies for ocular diseases. The collaboration leverages Catalent’s manufacturing expertise to accelerate clinical development of next-generation vision-restoring treatments.

Further strengthening the global biotech ecosystem, Samsung Biologics has partnered with Eli Lilly and Company to establish a Gateway Labs facility in Korea. The site will support up to 30 emerging biotech companies, fostering innovation and accelerating the transition from research to manufacturing.

Digital engagement in healthcare is also evolving rapidly. Veeva Systems has acquired Ostro to enhance AI-powered communication between patients, doctors, and life sciences brands. The platform enables real-time, compliant information delivery, improving engagement and decision-making.

In life sciences tools and genomics, MGI Tech has acquired STOmics and CycloneSEQ, strengthening its capabilities in spatial omics and sequencing technologies. This move positions the company as a comprehensive solutions provider in genomics and lab intelligence.

Among the largest deals, Novartis has completed its acquisition of Avidity Biosciences, valued at approximately $12 billion. The acquisition enhances Novartis’ RNA therapeutics portfolio, particularly in neuromuscular diseases, and signals growing interest in RNA-based drug development.

Similarly, GSK has finalized its acquisition of RAPT Therapeutics, adding a promising anti-IgE therapy for food allergies. The therapy’s extended dosing interval could significantly improve patient compliance and expand treatment access.

In the ADC space, WuXi XDC Cayman has partnered with Earendil Labs in a deal valued at up to $885 million. The collaboration integrates advanced payload-linker technology with AI-driven antibody discovery to accelerate development of next-generation cancer therapies.

Finally, IQVIA has announced the acquisition of discovery services assets from Charles River Laboratories. This move strengthens IQVIA’s end-to-end drug discovery capabilities, enabling seamless integration from early research to clinical development.

Overall, the breadth and scale of these deals reflect a rapidly evolving pharmaceutical landscape. Companies are increasingly investing in AI, biologics, and advanced manufacturing while pursuing strategic acquisitions to stay competitive. As innovation accelerates, the industry is poised to deliver more targeted, efficient, and patient-centric therapies, shaping the future of global healthcare.